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clinical constraints) and overdose comparable to the nominal 
case. Doses to organs at risk were similar for the three plans 
in both patients. 
 
 
Conclusion: The proposed strategies achieved robust plans in 
term of target coverage without increasing the dose to the 
CTV nor to the organs at risk. Full robust optimization gives 
better results than the mixed strategy, but the latter can be 
useful in cases where a MC engine is not available or too 
computationally intensive for beamlets calculation.  
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Purpose or Objective: The aim of the study was to develop a 
fully automated treatment planning procedure to generate 
VMAT plans for stage III/IV non-small cell lung cancer (NSCLC) 
patients, treated with curative intent, and to compare them 
with manually generated plans. 
 
Material and Methods: Based on treatment plans of 7 
previously treated patients, the clinical protocol, and 
physician’s treatment goals and priorities, our in-house 
developed system for fully automated, multi-criterial plan 
generation was configured to generate VMAT plans for 
advanced stage NSCLC patients without human interaction. 
For 41 independent patients, treated between January and 
August 2015, automatic plan generation was then compared 
with manual plan generation, as performed in clinical 
routine. Differences in PTV coverage, dose conformality R50 
(the ratio between the total volume receiving at least 50% of 
the prescribed dose and the PTV volume) and sparing of 
organs at risk were quantified, and their statistical 
significance was assessed using a Wilcoxon test. 
 
Results: For 35 out of 41 patients (85%), the automatically 
generated VMAT plans were clinically acceptable as judged 
by two physicians. Compared to the manually generated 
plans, they considered the quality of automatically generated 
plans superior for at least 67% of patients, due to a 
combination of better PTV coverage, dose conformality and 
sparing of lungs, heart and oesophagus (positive values in 
figure). For the other acceptable plans plan quality was 
considered equivalent. On average, PTV coverage (V95) was 
improved by 1.1 % (p<0.001), the near-minimum dose in the 
PTV (D99) by 0.55 Gy (p=0.006) and the R50 by 12.4% 
(p<0.001). The mean lung dose was reduced by 0.86 Gy 
(4.6%, p<0.001), and the V20 of the lungs by 1.3 % (p=0.001). 
For some patients it was possible to improve PTV V95 by 
3.8%, D99 by 3.3 Gy, to reduce mean lung dose by 3.0 Gy and 
V20 by 6.2%. All plans fulfilled the planning constraints for 
the spinal cord, heart and plexus. 
For the 6 automated VMAT plans that were initially not 
acceptable, it took a dosimetrist less than 10 minutes hands-
on time to manually fine-tune the VMAT plan in our TPS to 
make it acceptable. In contrast, to generate a VMAT plan 
from scratch 3-4 hours were required.  
For 5 out of 10 patients with a PTV prescription dose of less 
than 66 Gy in the manual plan, we were able to escalate the 
tumour dose using automated planning. For two patients dose 
escalation from 60 Gy to 66 Gy was possible, for other 
patients from 60.5 Gy to 66 Gy, 45 Gy to 57.75 Gy, and 55 Gy 
to 60.5 Gy, respectively. 
 
 
 
Conclusion: Using our fully automated treatment planning 
procedure, clinically deliverable, high quality VMAT plans for 
advanced stage NSCLC patients may be generated without 
human interaction for the far majority of patients. When 
manual adjustments were required, they took very little 
hands-on time only. With automated planning, a higher 
tumour dose could be achieved for a subgroup of patients. 
Clinical introduction has been started. 
 
OC-0267  
Fully automated planning for non-coplanar CyberKnife 
prostate SBRT - comparison with automatic VMAT 
L. Rossi
1Erasmus MC Cancer Institute, Radiation Oncology, 
Rotterdam, The Netherlands 
1, S. Breedveld1, S. Aluwini1, B. Heijmen1 
 
Purpose or Objective: In stereotactic body radiation 
therapy, high accuracy is required to deliver high fraction 
doses with steep dose gradients. Non-coplanar beam setups 
may improve plan quality. This can be realized with a robotic 
CyberKnife (CK, Accuray Inc, Sunnyvale, USA). Due to its 
tumor tracking features, CTV-PTV margins may be reduced 
compared to linac treatment. In previous works we have built 
and validated a system for fully automated, multi-criterial 
VMAT plan generation (iCycle/Monaco). Recently, we have 
extended the system with an option for fully automated plan 
generation for the CK (iCycle/Multiplan). In this study we 
have used fully automated plan generation for un-biased 
comparison of non-coplanar CK with coplanar VMAT at a 
linac, for prostate SBRT. 
 
Material and Methods: Our in-house iCycle system was first 
coupled to the Multiplan TPS that comes with the CK 
treatment unit. The iCycle/Multiplan and iCyle/Monaco 
systems were then configured for automated prostate SBRT 
plan generation for CK and linac-VMAT, respectively. Plans 
were then generated for 10 prostate SBRT patients, 
delivering 38 Gy in 4 fractions. Three clinically deliverable 
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plans were automatically generated for each patient, one for 
CK with 3 mm PTV margin, and two for VMAT with 3 and 5 
mm PTV margin, respectively. 
 
Results: With automated planning, high quality CK and VMAT 
plans could be generated without user dependency and trial-
and-error approach. PTV coverage was similar for the 3 
approaches, with on average a V100% of 95.2, 95.4%, and 
94.1% for CK, VMAT-3mm and VMAT-5mm. However, for some 
VMAT plans with 5mm margin, coverage > 95% was not 
feasible. Mean values for rectum D1cc were 26.1, 28.5, and 
34.3 Gy, for rectum Dmean 6.3, 7.1, and 10.8 Gy, for bladder 
D1cc 37.7, 37.3, and 39.4 Gy, and for bladder Dmean 8.7, 
7.5, and 9.2 Gy, for CK, VMAT-3mm and VMAT-5mm, 
respectively. Rectum doses were lower with CK compared to 
VMAT-3mm (p = 0.015 and p = 0.08 for rectum D1cc and 
Dmean) and highly decreased compared to VMAT-5mm (p = 
0.007 and 0.008). Bladder sparing worsened slightly with CK 
compared to VMAT-3mm, but this was not statistically 
significant. No relevant differences were found for other 
OARs. With CK, the low-medium dose bath was reduced 
compared to VMAT: V10Gy = 1157.5, 1525.6, 1741.8 cc, 
V20Gy = 286.3, 325.5, 382.0 cc, for CK, VMAT-3mm and 
VMAT-5mm, respectively, with p = 0.007 and p=0.008 for CK 
comparing to VMAT 3 and 5 mm. 
 
Conclusion: The first system for automated generation of 
clinically deliverable Cyberknife plans was built and used for 
unbiased plan comparison with VMAT at a linac. Optimized 
non-coplanar setups showed better rectum sparing compared 
to VMAT plans. This difference was especially large with the 
smaller CK CTV-PTV margin, possible with CyberKnife tumor 
tracking feature. 
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Purpose or Objective: Recently, iCycle/Monaco, a system for 
fully automated, multi-criterial plan generation, consisting of 
the in-house iCycle optimizer and Monaco (Elekta AB, 
Stockholm, Sweden) has been developed. Sofar, the system 
was only validated in a single institution. In this study, 
iCycle/Monaco was validated in 4 independent centers for 
prostate cancer VMAT. Hypothesis of the study was that 
automatically generated plans had similar or superior quality 
compared to plans generated by manual planning in clinical 
routine, using the Monaco TPS only. 
 
Material and Methods: For each of the 4 centers, plans of 10 
recently treated patients were used to configure 
iCycle/Monaco. For 20 independent patients, manually 
generated VMAT plans (MANplan) were then compared with 
automatically generated VMAT plans (AUTOplan). Plans were 
compared using dose-volume parameters and by ‘blind’ 
scoring by treating physicians. The scoring of the plans by 
physicians was performed in 2 sessions: A) the in total 40 
anonymized plans (20 AUTO, 20 MAN) were evaluated in 
random order to assess clinical acceptability, B) for each of 
the 20 patients, the AUTOplan and MANplan were compared 
to select the most favorable plan. In these comparisons, 
plans could be scored as i) of higher quality with a clinically 
relevant difference, ii) of higher quality but with a low 
clinical impact, or iii) of similar quality. In one participating 
center, plan scoring was performed independently by 2 
physicians. 
Results: A total of 200 separate plan evaluations and 100 
plan comparisons were made in this study. In the separate 
plan evaluations, 100% of MANplans and 98% of AUTOplans 
were clinically acceptable. The 2 AUTOplans that were not 
clinically acceptable had too high bowel dose, which was due 
to the absence of patients with small bowel delineation 
among the patients used for configuration of iCycle/Monaco 
in 2 centers. For 38/100 plan comparisons, the AUTOplan was 
considered superior to the MANplan, with high clinical 
relevance. Only in 9 comparisons, the MANplan was superior 
with high relevance for the patient. In all other comparisons, 
differences were absent or of minor clinical relevance 
(Figure). With similar PTV coverage, dose delivery to OARs 
was on average lower for the AUTOplans: -14.8%, -24.6%, and 
-14.6% for rectum V75, V60, and Dmean (p=0.001, p<0.001, 
p<0.001), and -5.1% for bladder Dmean (p=0.009). 
 
Frequency histogram showing the scores for 100 comparisons 
of an automatically (AUTO) and a manually (MAN) generated 
plan.  
 
Conclusion: In an international, multi-institutional setting, 
automatic planning for prostate cancer has proven to be 
overall superior to manual planning. Automated planning 
avoids planning workload and contributes to standardized 
radiotherapy treatment with high plan quality. 
 
Proffered Papers: RTT 3: Ensuring quality in head and neck 
treatment  
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Purpose or Objective: Simultaneously integrated boost (SIB) 
used in many sites, replanning is not made. In SIB of 
intensity-modulated radiotherapy (IMRT), doses per fraction 
are often unconventional, because of equal fractions treating 
multiple targets. We assessed sequential SIB (SEQ-SIB) to 
resolve the problem. The purpose of this study is to compare 
dosimetric parameters of SEQ-SIB with those of SIB using 
deformable imaging registration (DIR) for head and neck 
cancer patients. 
 
Material and Methods: Subjects were 10 cases HNC treated 
with IMRT at our institute in 2014. In all cases, high-risk 
planning target volume (PTVboost) was based on the primary 
tumor and clinical lymph node metastases, while 
PTVelective(PTVel) included bilateral cervical nodal areas. 
The D95 was defined as the prescribed dose. For SIB, doses 
were 66 and 54 Gy in 30 fractions to PTVboost and PTVel, 
respectively. For SEQ-SIB, they were 55 Gy to PTVboost and 
50 Gy to PTVel in 25 fractions using SIB, followed by 11 Gy in 
5 fractions to PTVboost.We chose to maintain the size of the 
